biochimica clinica

en_US English
en_US English it_IT Italian

DOCUMENTI - Documents

Volume:

Biochimica Clinica 2023; 47(2) 191-203

Pubblicato on-line:

February 15, 2023

DOI:

10.19186/BC_2023.008

Scarica in PDF:
Autenticazione richiesta

Programma scientifico del Gruppo di Studio SIBioC-ELAS dei Biomarcatori Cardiaci (triennio 2021-2023)
Italian Study Group on cardiovascular risk factors: Scientific Program (years 2021-2023)

AUTORI

Aldo Clerico (Pisa), Martina Zaninotto (Padova) Coordinatori del Gruppo di Studio

ABSTRACT

Italian Study Group on cardiovascular risk factors: Scientific Program (years 2021-2023)

The principal aim of this document is to provide a detailed documentation of the scientific activity carried out by the Italian Study Group on Cardiovascular biomarkers during these last three difficult years characterized by COVID-19 pandemic, that has put in strain the activity of all clinical laboratories (not only in Italy). Another important aim of this document is to discuss some important pathophysiological and clinical issues related to cardiac-specific biomarkers (i.e., cardiac natriuretic peptides and cardiac troponins), that still need not only further theoretical investigation, but also some multicenter clinical trials in order to evaluate and to improve their utilization in diagnosis, prognosis and managing of patients with cardiovascular disease

BIBLIOGRAFIA

  1. Sackett Dl, Haynes RB, Guyatt GH, Tudwell P. Clinical Epidemiology. A basic science for clinical medicine. Second Edition. Little, Brown and Company, Boston, 1991.
  2. Pepe MS. The statistical evaluation of medical test for classification and prediction. Oxford Statistical Science Series, vol 31. Oxford University Press 2003, New York.
  3. Fletcher RH, Flectcher SW, Flectcher GS. Clinical Epidemiology. The essentials. Fifth Edition. Wolters Kluwer/Lippincott Williams &Wilkins. Philadelphia 2014.
  4. Thygesen K, Alpert JS, Jaffe AS, et al., ESC Scientific Document Group. Fourth Universal Definition of Myocardial Infarction (2018). Eur Heart J 2019;40:237-69.
  5. Clerico A, Padoan A, Zaninotto M, Plebani M. Clinical relevance of biological variation of cardiac troponins. Clin Chem Lab Med 2020;59:641-52.
  6. Giannoni A, Giovannini S, Clerico A. Measurement of circulating concentrations of cardiac troponin I and T in healthy subjects: a tool for monitoring myocardial tissue renewal? Clin Chem Lab Med 2009;47:1167-77.
  7. Caselli C, Cangemi G, Masotti S, et al. Plasma cardiac troponin I concentrations in healthy neonates, children and adolescents measured with a highly sensitive immunoassay method: Highly sensitive troponin I in pediatric age. Clin Chim Acta 2016;458:68-71.
  8. Perrone MA, Storti S, Salvadori S, et al. Cardiac troponins: are there any differences between T and I. J Cardiovasc Med 2021; 22:797-805.
  9. Giannitsis E, Mueller C, Katus HA. Skeletal myopathies as a non-cardiac cause of elevations of cardiac troponin concentrations. Diagnosis 2019;6:189-201.
  10. Aggarwal R, Lebiedz-Odrobina D, Sinha A, et al. Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies. J Rheumatol 2009;36:2711.
  11. Cox F, Delgado V, Verschuuren J, et al. The heart in sporadic inclusion body myositis: a study in 51 patients. J Neurol 2010;257:447-51.
  12. Jaffe AS, Vasile VC, Milome M, et al. Diseased skeletal muscle. A noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol 2011:58:1819-24.
  13. Rittoo D, Jones A, Lecky B, et al. Elevation of cardiac troponin T, but not cardiac troponin I, in patients with neuromuscular diseases. J Am Coll Cardiol 2014;63:2411-20.
  14. Hughes M, Lilleker VB, Herrick AL, et al. Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low grade skeletal muscle disease activity. Ann Rheum Dis 2015;74:795-8.
  15. Schmid J, Liesinger L, Bimer-Gruenberg R, et al. Elevated cardiac troponin T in patients with skeletal myopathies. J Am Coll Cardiol 2018;71:1540-9.
  16. Clerico A, Zaninotto M, Passino C, et al. Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers. Clin Chem Lab Med 2020;59:79-90.
  17. Farmakis D, Mueller C, Apple FS. High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population. Eur Heart J 2021;41:4050-6.
  18. Mair J, Lindahl B, Hammarsten O, et al. How is cardiac troponin released from injured myocardium?. Eur Heart J Acute Cardiovasc Care 2018;7:553-60.
  19. Marjot J, Kaier TE, Martin ED, et al. Quantifying the release of biomarkers of myocardial necrosis from cardiac myocytes and intact myocardium. Clin Chem 2017;63:990–6.
  20. Perrone MA, Zaninotto M, Masotti S, et al. The combined measurement of high-sensitivity cardiac troponins and natriuretic peptides: a useful tool for clinicians? J Cardiovasc Med 2020;21:953-63.
  21. Wu AHB, Christenson RH, Greene DN, et al. Clinical laboratory practice recommendations for the use of cardiac troponin in acute coronary syndrome: Expert opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem 2018;64:645-55.
  22. Januzzi JL Jr, Mahler SA, Christenson RH, et al. Recommendations for institutions transitioning to high-sensitivity troponin testing. JAAC Scientific Expert Panel. J Am Coll Cardiol 2019;73:1059-77.
  23. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2020;ehaa575. doi: 10.1093/eurheartj/ehaa575. Online ahead of print.
  24. Clerico A, Cardinale DM, Zaninotto M, et al. High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy. Clin Chem Lab Med 2020; 59:513-521.
  25. Cardinale DM, Zaninotto M, Cipolla CM, et al. Cardiotoxic effects and myocardial injury: the search for a more precise definition of drug cardiotoxicity. Clin Chem Lab Med 2020; 59:51-57.
  26. Clerico A, Zaninotto M, Ripoli A, et al. The 99th percentile of reference population for cTnI and cTnT assay: methodology, pathophysiology and clinical implications. Cliun Chem Lab Med 2017;55:1634-51.
  27. Clerico A, Ripoli A, Zaninotto M, et al. Head-to-head comparison of plasma cTnI concentration values measured with three high-sensitivity methods in a large Italian population of healthy volunteers and patients admitted to emergency department with acute coronary syndrome: A multi-center study. Clin Chim Acta 2019;496:25-34.
  28. Hlatky MA, Greenland P, Arnett DK, et al.; on behalf of the American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a Scientific Statement from the American Heart Association. Circulation. 2009;119:2408-16.
  29. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011;123:551-65.
  30. Barabasi AL. Network science. Cambridge University Press, 2016.
  31. Newman M. Networks: an introduction. OUP Oxford press, 201. Clerico A, Ripoli A, Fortunato A, et al. Harmonization protocols for TSH immunoassays: a multicenter study in Italy. Clin Chem Lab Med 2017;55:1722-33.
  32. Clerico A, Ripoli A, Fortunato A, et al., on behalf of the Italian Section of the European Ligand Assay Society (ELAS). Harmonization protocols for TSH immunoassays: a multicenter study in Italy. Clin Chem Lab Med 2017;55: 1722–33.
  33. Aspromonte N, Gulizia MM, Clerico A, et al. ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure. Eur Heart J Suppl 2017;19 Suppl D D102-12.
  34. Masotti S, Prontera C, Musetti V, et al. Evaluation of analytical performance of a new high-sensitivity immunoassay for cardiac troponin I. Clin Chem Lab Med 2018;56:492-501.
  35. Clerico A, Zaninotto M, Masotti S, et al. Valutazione delle caratteristiche analitiche dei metodi di misura delle troponine cardiache I e T: dalla teoria alla pratica di laboratorio. Documento congiunto del Gruppo di Studio Biomarcatori Cardiovascolari di SIBioC-Medicina di Laboratorio ed European Ligand Assay Society (ELAS). Biochimica Clinica 2018;42:155-66.
  36. Clerico A, Zaninotto M, Graziani MS, et al. Quality specifications, terminology and definition of the methods for the measurement of cardiac troponins. Biochimica Clinica 2018; 42:343-6.
  37. Musetti V, Masotti S, Prontera C, et al. Evaluation of the analytical performance of a new ADVIA immunoassay using the Centaur XPT platform system for the measurement of cardiac troponin I. Clin Chem Lab Med 2018;56:e229-31.
  38. Masotti S, Musetti V, Prontera C, et al. Evaluation of analytical performance of a chemiluminescence enzyme immunoassay (CLEIA) for cTnI using the automated AIA-CL-2400 platform. Clin Chem Lab Med 2018;56:e174-6.
  39. Clerico A, Zaninotto M, Padoan A, et al. Evaluation of analytical performance of immunoassay methods for cTnI and cTnT: From theory to practice. Adv Clin Chem 2019;93:239-62.
  40. Clerico A, Ripoli A, Masotti S, et al. Evaluation of 99th percentile and reference change values of a high sensitivity cTnI method: A multicenter study. Clin Chim Acta 2019; 493:156-61.
  41. Clerico A, Masotti S, Musetti V, et al. Evaluation of 99th percentile and reference change values of the hs-cTnI method using ADVIA Centaur XPT platform: A multicenter study. Clin Chim Acta 2019; 495:161-6.
  42. Ndreu R, Musetti V, Masotti S, et al. Evaluation of reproducibility of the cTnT immunoassay using quality control samples. Clin Chim Acta 2019; 495:269-70.
  43. Masotti S, Musetti V, Prontera C, et al. Evaluation of analytical performances using standardized analytical protocols and comparison of clinical results of the new ADVIA BNP and NT-proBNP immunoassays for the Centaur XPT platform. Clin Chem Lab Med 2019;57:911-7.
  44. Musetti V, Masotti S, Prontera C, et al. Evaluation of reference change values for a hs-cTnI immunoassay using both plasma samples of healthy subjects and patients and quality control samples. Clin Chem Lab Med 2019; 57:e241-e243.
  45. Masotti S, Musetti V, Aloe R, et al. Evaluation of 99th percentile value of a chemiluminescence enzyme immunoassay (CLEIA) for cTnI using the automated AIA-CL2400 platform. Clin Chim Acta 2019;496:45-7.
  46. Clerico A, Zaninotto M, Padoan A, et al. Harmonization of two hs-cTnI methods based on recalibration of measured quality control and clinical samples. Clin Chim Acta 2020;510:150-6.
  47. Storti S, Zaninotto M, Musetti V, et al. Le troponine I e T sono biomarcatori cardiaci interscambiabili? Biochimica Clinica 2020; 44 Suppl1:S8-S16.
  48. Passino C, Zaninotto M, Masotti S, et al. La misura combinata dei biomarcatori cardio-specifici è utile nei pazienti con sospetto di malattie cardiovascolari. Biochimica Clinica 2020; 44(SS1):S17-S31.
  49. Zaninotto M, Clerico A, Plebani M. Patologie cardiovascolari e troponine cardiache: la storia di un legame indissolubile. Biochimica Clinica 2020; 44(SS1):S67-S73.
  50. Aspromonte N, Zaninotto M, Padoan A, et al. Valutazione del rischio cardiovascolare e del danno cardiaco asintomatico nella popolazione generale utilizzando la misura della troponina cardiaca con metodi ad alta sensibilità. Documento del Gruppo di Studio Inter-societario sui Biomarcatori Cardiaci. Biochimica Clinica 2020; 44 Suppl 1:S86-S96.
  51. Caselli C, Ragusa R, Prontera C, et al. Distribution of circulating cardiac biomarkers in healthy children: from birth through adulthood. Biomark Med 2016:10:357-65.
  52. Perrone MA, Passino C, Vassalle C, et al. early evaluation of myocardial injury by means of high-sensitivity methods for cardiac troponins after strenuous and prolonged exercise. J Sports Med Phys Fitness 2020;60:1297-305.
  53. Perrone MA, Macrini M, Maregnani A, et al. The effects of a 50 km ultramarathon race on high sensitivity cardiac troponin I and NT-proBNP in highly trained athletes. Minerva Cardioangiol 2020;68:305-12.
  54. Cantinotti M, Clerico A, Giordano R et al. Cardiac troponin-T release after sport and differences by age, sex, training type, volume, and intensity: A critical review. Clin J Sport Med 2022;32:e230-42.
  55. Ragusa R, Di Molfetta A, Amodeo A, et al. Pathophysiology and molecular signalling in pediatric heart failure and VAD therapy. Clin Chim Acta 2020;510:751-759.
  56. Padoan A, Clerico A, Zaninotto M, et al. Percentile transformation and recalibration functions allow harmonization of thyroid-stimulating hormone (TSH) immunoassay results. Clin Chem Lab Med 2020;58:1663-72.
  57. Clerico A, Aimo A, Cantinotti M. High-sensitivity cardiac troponins in pediatric population. Clin Chem Lab Med 2021; 25:60:18-32.
  58. Clerico A, Aimo A, Cantinotti M. Cardiac biomarkers for outcome prediction in infant bronchiolitis: Too soon to discard troponin? Clin Chim Acta 2021; 518:170-172.
  59. Eijsvogels TM, Fernandez AB, Thompson PD. Are there deleterious cardiac effects of acute and chronic endurance exercise? Physiol Rev 2016;96:99-125.
  60. Aakre KM, Omland T. Physical activity, exercise and cardiac troponins: clinical implications. Prog Cardiovasc Dis 2019;62:108-15.
  61. Giannitsis E, Mueller-Hennessen M, Zeller T, et al. Gender-specific reference values for high-sensitivity cardiac troponin T and I in well-phenotyped healthy individuals and validity of high-sensitivity assay designation. Clin Biochem 2020;78:18-24.
  62. Mueller T, Egger M, Peer E, et al. 5th generation cardiac troponin I and T assays in clinical routine – A head-to-head comparison with data from the Linz troponin (LITROP) study. Clin Chim Acta 2018;485:195-204.
  63. Mueller T, Egger M, Peer E, et al. Evaluation of sex-specific cut-off values of high-sensitivity cardiac troponin I and T assays in an emergency department setting – Results from the Linz Troponin (LITROP) study. Clin Chim Acta 2018;487:66-74.
  64. Sandoval Y, Apple FS. The global need to define normality: the 99th percentile value of cardiac troponin. Clin Chemm 2014;60:455-62.
  65. Apple FS, Sandoval Y, Jaffe AS, et al. IFCC Task Force on Clinical Application of Cardiac Bio-Markers. Cardiac troponin assays: guide to understanding analytical characteristics and their impact on clinical care. Clin Chem 2017;63:73-81.
  66. Peacock WF. Time to treatment and acute coronary syndromes: bridging the gap in rapid decision making. Rev Cardiovasc Med 2010;11 2 Suppl S45–50.
  67. Everett BM, Zeller T, Glynn RJ, et al. Events in primary prevention. Impact of statin therapy. Circulation 2015; 131:1851–60.
  68. Shalaby AA, Abraham WT, Fonarow GG, et al. Association of BNP and troponin levels with outcome among cardiac resynchronization therapy recipients. Pacing Clin Electrophysiol 2015;38:581–90.
  69. du Fay de Lavallaz J, Badertscher P, Nestelberger T, et al. B-type natriuretic peptides and cardiac troponins for diagnosis and risk-stratification of syncope. Circulation 2019;139:2403–18.
  70. Franzini M, Lorenzoni V, Masotti S, et al. The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: a multicenter study in Italy. Clin Chim Acta 2015;438:376–81.
  71. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014;35:2383-431.
  72. Karakas M, Koenig W. Improved peri-operative risk stratification in non-cardiac surgery: going beyond established clinical scores. Eur Heart J 2013;34:796-8.
  73. Clerico A, Emdin M, Passino C. Cardiac biomarkers and risk assessment in patients undergoing major non-cardiac surgery: time to revise the guidelines? Clin Chem Lab Med 2014;52:959-63.
  74. Kalesan B, Nicewarner H, Intwala S, et al. Pre-operative stress testing in the evaluation of patients undergoing non-cardiac surgery: a systematic review and meta-analysis. PLoS ONE 2019;14:e0219145.
  75. Cao D, Chandiramani R, Capodanno D, et al. Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management. Nat Rev Cardiol 2021;18:37-57.
  76. Struthers A, Lang C. The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent ‘pancardiac’ target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney. Eur Heart J 2007;28:1678–82.
  77. Duceppe E, Parlow J, MacDonald P, et al. Canadian Cardiovascular Society guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery. Can J Cardiol 2017;33:17-32.
  78. Costa MCDBG, Furtado MV, Borges FK, et al. Perioperative troponin screening identifies patients at higher risk for major cardiovascular events in noncardiac surgery. Curr Probl Cardiol 2021;46:1000429.
  79. Serrano AB, Gomez-Rojo M, Ureta E et al. Preoperative clinical model to predict myocardial injury after non-cardiac surgery: a retrospective analysis from the MANAGE cohort in a Spanish hospital. BMJ open 2021;11:e045052.
  80. Turan A, Cohen B, Rivas E, et al. Association between postoperative haemoglobin and myocardial injury after noncardiac surgery: a retrospective cohort analysis. Br J Anaesthesiol 2021;126:94-10.
  81. Górka J, Polok K, Fronczek J, et al. Myocardial injury is more common than deep venous thrombosis after vascular surgery and is associated with a high one year mortality risk. Eur J Vasc Endovasc Surg 2018;56:264-70.
  82. Ackland GL, Abbott TEF, Jones TF, et al. VISION-UK Investigators. Early elevation in plasma high-sensitivity troponin T and morbidity after elective noncardiac surgery: prospective multicentre observational cohort study. Br J Anaesth 2020;124:535-43.
  83. Borg Caruana C, Jackson SM, Ngyuen Khuong J, et al. Systematic review and meta-analysis of postoperative troponin as a predictor of mortality and major adverse cardiac events after vascular surgery. J Vasc Surgery 2020;72:1132-43.
  84. Lowe MJ, Lighfoot NJ. The prognostic implication of perioperative cardiac enzyme elevation in patients with fractured neck of femur: A systematic review and meta-analysis. Injury 2020;51:164-73.
  85. Moon YJ, Kwon HM, Jung KW, et al. Preoperative high-sensitivity troponin I and B-type natriuretic peptide, alone and in combination, for risk stratification of mortality after liver transplantation. Korean J Anesthesiol 2021;74:242-53.
  86. Kler A, Dave M, Blatatzis M, et al. Elevation of high-sensitive Troponin T predicts mortality after open pancreaticoduodenectomy. World J Surg 2021;45:1913–20.
  87. Clerico A, Zaninotto M, Aimo A, et al. Evaluation of the cardiovascular risk in patients undergoing major non-cardiac surgery: role of cardiac-specific biomarkers. A consensus document by the Inter-Society Study Group on Cardiac Biomarkers of the Italian Societies of Clinical Biochemistry: European Ligand Assay Society (ELAS), Italian section; Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica (SIBioC); Società Italiana di Patologia Clinica e Medicina di Laboratorio (SIPMel). Clin Chem Lab Med 2022:60:1525-42.
  88. López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, et al. Classification, prevalence, and outcome of anticancer therapy-indiced cardiotoxicity: the CARDIOTOX registry. Eur Heart J 2020;41:1720-9.
  89. Chang HM, Moudgil R, Scarabelli T, et al. Cardiovascular complications of cancer therapy best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol 2017;70:2536–51.
  90. Chang HM, Okwuosa TM, Scarabelli T, et al. Cardiovascular complications of cancer therapy best practices in diagnosis, prevention, and management: part 2. J Am Coll Cardiol 2017;70:2552–65.
  91. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213–220.
  92. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;133:1981–8.
  93. Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al.; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016;37:2768–801.
  94. Cardinale DM, Zaninotto M, Cipolla CM, et al. Cardiotoxic effects and myocardial injury: the search for a more precise definition of drug cardiotoxicity. Clin Chem Lab Med 2021;59:51-7.
  95. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-54
  96. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy–induced cardiotoxicity in high-risk patients by Angiotensin-Converting Enzyme Inhibition. Circulation 2006;114:2474-81.
  97. Cao L, Zhu W, Wagar EA, et al. Biomarkers for monitoring chemotherapy-induced cardiotoxicity. Crit Rev Clin Lab Sci 2017;54:87-101.
  98. Gülgün M, Fidancı K, Genç FA, et al. Natriuretic peptide and cardiac troponin levels in doxorubicin-induced cardiotoxicity. Anatol J Cardiol 2016;16:299.
  99. Cardinale D, Biasillo G, Salvatici M, et al. Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. Expert Rev Mol Diagn 2017;17:245-56.
  100. Kitayama H, Kondo T, Sugiyama J, et al. High-sensitive troponin T assay can predict anthracyclineand trastuzumab-induced cardiotoxicity in breast cancer patients. Breast Cancer 2017;24:774-82.
  101. Jones M, O’Gorman P, Kelly C, et al. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury. Ann Clin Biochem 2017;54:149-57.
  102. Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis 2018;10 Suppl 35:S4282-95.
  103. Riddell E, Lenihan D. The role of cardiac biomarkers in cardio-oncology. Curr Probl Cancer 2018;42:375-85.
  104. Sarocchi M, Arboscello E, Bellodi A, et al. Serial Troponin for early detection of Nivollumab cardiotoxicity in advanced non-small cell lung cancer patients. Oncologist 2018;23:936-42.
  105. Simões R, Silva LM, Valle Mussi Cruz AL, et al. Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy: A narrative review. Biomed Pharmacother 2018;107:989-96.
  106. Sandoval Y, Sharin K, Saenger AK, Smith SW, Apple FS, Jaffe AS. Clinical use of cardiac troponin for acute cardiac care and emerging opportunities in the outpatients setting. Minerva Med 2019;110:139-56.
  107. Cardinale D, Ciceri F, Latini R, et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer 2018;94:126-37.
  108. Clerico A, Cardinale DM, Zaninotto M, et al. High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy. Clin Chem Lab Med 2021;59:513-21.
  109. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229-361
  110. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 2022;43:280-99.
  111. Clerico A, Zaninotto M, Aimo A, Cardinale DM, Dittadi R, Sandri MT et al. Variability of cardiac troponin levels in normal subjects and in patients with cardiovascular diseases: analytical considerations and clinical relevance. A consensus document by the Study Group on Cardiac Biomarkers from Italian Society of Biochemical Chemistry (SIBioC) and European Ligand Assay Society (ELAS). Clin Chem Lab Med 2023 doi: 10.1515/cclm-2022-1285 (ahead of print).
  112. Bergami M, Scarpone M, Bugiardini R, Cenko E, Manfrini O. Sex beyond cardiovascular risk factors and clinical biomarkers of cardiovascular disease. Rev Cardiovasc Med 2022;23:019.
  113. Perrone MA, Aimo A, Bernardini S, Clerico A. Inflammageing and cardiovascular system: Focus on cardiokines and cardiac-specific biomarkers. Int J Biol Sci 2023;24:844.
  114. Cediel G, Codina P, Spitaleri G, et al. Gender-related differences in heart failure biomarkers. Front Cardiovasc Med 2021;7:617705.
  115. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021, 42, 35993726.
  116. Magnussen C, Niiranen TJ, Ojeda FM, et al. Sex-Specific epidemiology of heart failure risk and mortality in Europe: results from the BiomarCaRE consortium. JACC Heart Fail 2019;7:204-13.
  117. Scantlebury DC, Borlaug BA. Why are women more likely than men to develop heart failure with preserved ejection fraction? Curr Opin Cardiol 2011;26:562-8.
  118. Reue K, Wiese CB. Illuminating the mechanisms underlying sex differences in cardiovascular disease. Circ Res 2022;130:1747-62.
  119. Cantonotti M, Clerico A, Giordano R, et al. Cardiac Troponin-T release after sport and differences by age, sex, training type, volume, and intensity: A critical review. Clin J Sport Med 2022;32:e230-40.
  120. Shave R, George KP, Atkinson G, et al. Exercise-induced cardiac troponin T release: a meta-analysis. Med Sci Sports Exerc. 2007;39:2099-106.
  121. Vilela EM, Bastos JC, Rodrigues RP, et al. High-sensitivity troponin after running-a systematic review. Neth J Med. 2014;72:5-9.
  122. Cirer-Sastre R, Legaz-Arrese A, Corbi F, et al. Cardiac biomarker release after exercise in healthy children and adolescents: a systematic review and meta-analysis. Pediatr Exerc Sci 2019;31:28–36.
  123. Baker P, Leckie T, Harrington D, et al. Exercise-induced cardiac troponin elevation: an update on the evidence, mechanism and implications. Int J Cardiol Heart Vasc 2019;22:181–186.
  124. Lee IM, Skerrett PJ. Physical activity and all-cause mortality: what is the dose-response relation? Med Sci Sports Exerc 2001;33 Suppl. 6:S459-71.
  125. Kohl HW. Physical activity and cardiovascular disease: evidence for a dose response. Med. Sci. Sports Exerc 2001;33 Suppl. 6:S472-83.
  126. Chin SH, Kahathuduwa CN, Binks M. Physical activity and obesity: what we know and what we need to know. Obes Rev 2016;17:1226-44.
  127. Hallal PC, Andersen LB, Bull FC, et al. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet 2012;380:247-57.
  128. Lobelo F, Stoutenberg M, Hutber A. The exercise is medicine global health initiative: a 2014 update. Br J Sports Med 2014;48:1627-33.
  129. Henschel B, Gorczyca AM, Chomistek AK. Time spent sitting as an independent risk factor for cardiovascular disease. Am J Lifestyle Med 2017;155982761772848:204-15.
  130. Thompson PD, Eijsvogels TMH. New physical activity guidelines: a call to activity for clinicians and patients. JAMA 2018;320:1983-4.
  131. Shrestha N, Kukkonen-Harjula KT, Verbeek JH, et al. Workplace interventions for reducing sitting at work. Cochrane Database Syst Rev 2018;12:CD010912.
  132. Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med 2020;54:1451-62.
  133. Tiller NB, Stewart GM, Illidi CM, et al. Exercise is medicine? The cardiorespiratory implications of ultra-marathon. Curr Sports Med Rep 2020;19:290-7.
  134. Izquierdo M, Merchant RA, Morley JE, et al. International exercise recommendations in holder adults (ICFSR): Expert Consensus Guidelines. J Nutr Health Aging 202;25:824-53.
  135. Hanssen H, Boardman H, Deiseroth A, et al. Personalized exercise prescription in the prevention and treatment of arterial hypertension: a Consensus Document from the European Association of Preventive Cardiology (EAPC) and the ESC Council on Hypertension. Eur J Prev Cardiol 2022;29:205-15.
  136. Pelliccia A, Solberg EE, Papadakis M, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2019;40:19-33.
  137. Willeit P, Welsh P, Evans JDW, et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants. J Am Coll Cardiol 2017;70:558-68.
  138. Lam CSP, Castillo R, Ho Dt, et al. High-sensitivity troponin I for cardiovascular risk stratification in the general asymptomatic population: Perspectives from Asia-Pacific. Int J Cardiol 2019;282:93-8.
  139. Broersen LHA, Stengl H, Nolte CH, et al. Association between high-sensitivity cardiac troponin and risk of stroke in 96 702 individuals: A meta-analysis. Stroke 2020;51:1085-93.
  140. Raber I, McCarthy CP, Januzzi JL. A test in context: Interpretation of high-sensitivity cardiac troponin assays in different clinical settings. J Am Coll Cardiol 2021;77:1357-67.
  141. Sze J, Mooney J, Barzi F, et al. Cardiac troponin and its relationship to cardiovascular outcomes in community populations – A systematic review and meta-analysis. Heart Lung Circ  2016;25:217-28.
  142. Van der Lindel N, Klinkenberg LJJ, Bekers O, Loon LJCV, Dieijen-Visser MPV, Zeegers MP, et al. Prognostic value of basal high-sensitive cardiac troponin levels on mortality in the general population: a meta-analysis. Medicine 2016;95:e5703.
  143. Willeit P, Welsh P, Evans JDW, Tschiderer L, Boachie C, Jukema JW, et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants. J Am Coll Cardiol 2017;70:558-68.
  144. Hughes MF, Ojeda F, Saarela O, et al. Association of repeatedly measured high-sensitivity-assayed troponin I with cardiovascular disease events in a general population from the MORGAM/BiomarCaRE Study. Clin Chem 2017;63:334-42.
  145. Sigurdardottir FD, Lynbakken MN, Holmen OL, Dalen H, Hveem K, Røsjø H, Omland T. Relative prognostic value of cardiac troponin I and C-reactive protein in the general population (from the North-Trøndelag Health [HUNT] Study). Am J Cardiol 2018;121:949-55.
  146. Welsh P, Preiss D, Shah ASV, et al. Comparison between high-sensitivity cardiac troponin T and cardiac troponin I in a large general population cohort. Clin Chem 2018;64:1607-16.
  147. Lippi G, Cervellin G, Sanchis-Gomar F. Predicting mortality with cardiac troponins: recent insights from meta-analyses. Diagnosis 2019;8:37-49.
  148. Aimo A, Georgiopoulos G, Panichella G,  et al. High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis. Eur J Intern Med 2022;98:61-8.
  149. Gresslien T, Agewall S. Troponin and exercise. Int J Cardiol 2016;609-21.